Anup K Majumdar
Overview
Explore the profile of Anup K Majumdar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majumdar A, Yan K, Selverian D, Barlas S, Constanzer M, Dru J, et al.
J Clin Pharmacol
. 2007 Apr;
47(6):744-50.
PMID: 17463213
Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam...
2.
Mistry G, Majumdar A, Swan S, Sica D, Fisher A, Xu Y, et al.
J Clin Pharmacol
. 2006 Sep;
46(10):1128-38.
PMID: 16988201
Ertapenem is a parenteral beta-lactam carbapenem antibiotic. This open-label study examined the pharmacokinetics of single 1-g intravenous doses of ertapenem, administered over 30 minutes, in patients with mild, moderate, and...
3.
Majumdar A, Howard L, Goldberg M, Hickey L, Constanzer M, Rothenberg P, et al.
J Clin Pharmacol
. 2006 Feb;
46(3):291-300.
PMID: 16490805
Aprepitant is the first NK1 receptor antagonist approved for use with corticosteroids and 5HT3 receptor antagonists to prevent chemotherapy-induced nausea and vomiting (CINV). The effective dose to prevent CINV is...
4.
Nix D, Majumdar A, DiNubile M
J Antimicrob Chemother
. 2004 May;
53 Suppl 2:ii23-8.
PMID: 15150180
Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral beta-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been...
5.
Bergstrom M, Hargreaves R, Burns H, Goldberg M, Sciberras D, Reines S, et al.
Biol Psychiatry
. 2004 May;
55(10):1007-12.
PMID: 15121485
Background: Aprepitant is a highly selective substance P (neurokinin 1 [NK(1)] receptor) antagonist that significantly improves the pharmacotherapy of acute and delayed highly emetogenic chemotherapy-induced nausea and vomiting, probably through...
6.
Shadle C, Lee Y, Majumdar A, Petty K, Gargano C, Bradstreet T, et al.
J Clin Pharmacol
. 2004 Feb;
44(3):215-23.
PMID: 14973304
The NK(1) receptor antagonist aprepitant (EMEND(R)), developed for use in combination with a 5HT(3) receptor antagonist and a corticosteroid to prevent highly emetogenic chemotherapy-induced nausea and vomiting (CINV), has been...
7.
Feuring M, Lee Y, Orlowski L, Michiels N, De Smet M, Majumdar A, et al.
J Clin Pharmacol
. 2003 Sep;
43(8):912-7.
PMID: 12953348
Aprepitant is a highly selective neurokinin-1 receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine3 (5HT3) receptor antagonist, has been shown to be efficacious in the prevention of...
8.
Majumdar A, McCrea J, Panebianco D, Hesney M, Dru J, Constanzer M, et al.
Clin Pharmacol Ther
. 2003 Aug;
74(2):150-6.
PMID: 12891225
Background: Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Because aprepitant...
9.
McCrea J, Majumdar A, Goldberg M, Iwamoto M, Gargano C, Panebianco D, et al.
Clin Pharmacol Ther
. 2003 Jul;
74(1):17-24.
PMID: 12844131
Background: Aprepitant is a neurokinin(1) receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine(3) receptor antagonist, has been shown to be very effective in the prevention of chemotherapy-induced...
10.
Musson D, Birk K, Kitchen C, Zhang J, Hsieh J, Fang W, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2002 Nov;
783(1):1-9.
PMID: 12450519
Ertapenem is a new once-a-day antibiotic with excellent coverage of common community gram negative and gram positive aerobes and anaerobes. It demonstrates nonlinear protein binding in human plasma (about 94%...